Cover Image
市場調查報告書

白樺花粉症:開發平台分析

Birch Pollen Allergy - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 200930
出版日期 內容資訊 英文 49 Pages
訂單完成後即時交付
價格
Back to Top
白樺花粉症:開發平台分析 Birch Pollen Allergy - Pipeline Review, H2 2016
出版日期: 2016年07月20日 內容資訊: 英文 49 Pages
簡介

白樺花粉過敏是由於白樺的花粉引發的花粉症之一,在春天造成原因不明的眼·鼻子的症狀。白樺花粉造成的鼻子過敏症狀包含與感冒和流感類似的症狀(不包含發燒),症狀包括噴嚏,喘鳴和呼吸不足造成的呼吸障礙,鼻塞,結膜炎等。通常使用抗組織胺藥物和非鎮壓型抗組織胺藥物、過敏抑製藥、皮質類固醇、鼻塞抑制劑等治療藥處方。

本報告提供全球各國治療白樺花粉症用的開發中產品之開發情形相關分析,提供您開發中產品的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要(產品概要,功能機制,研究開發(R&D)的發展情形),最新的產業趨勢等調查,並將結果概述為以下內容。

簡介

  • 分析範圍

白樺花粉症概要

治療藥的開發

  • 白樺花粉過敏開發中產品:概要
  • 白樺花粉過敏開發中產品:比較分析

企業正在開發的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的開發企業

  • ALK-Abello A/S
  • Allergopharma Joachim Ganzer KG
  • Anergis SA
  • Biomay AG
  • Circassia Pharmaceuticals Plc
  • HAL Allergy BV
  • Stallergenes S.A.

治療藥的評估

  • 單劑產品
  • 標的別
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis
  • Allergen for Birch Pollen Induced Allergic Rhinoconjunctivitis
  • AllerT
  • Birch-SPIRE
  • BM-31
  • PL-102
  • rBet v1
  • rBet v1-FV
  • STG-210

最新開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8255IDB

Summary

Global Markets Direct's, 'Birch Pollen Allergy - Pipeline Review, H2 2016', provides an overview of the Birch Pollen Allergy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Birch Pollen Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Birch Pollen Allergy and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Birch Pollen Allergy
  • The report reviews pipeline therapeutics for Birch Pollen Allergy by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Birch Pollen Allergy therapeutics and enlists all their major and minor projects
  • The report assesses Birch Pollen Allergy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Birch Pollen Allergy

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Birch Pollen Allergy
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Birch Pollen Allergy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Birch Pollen Allergy Overview
  • Therapeutics Development
    • Pipeline Products for Birch Pollen Allergy - Overview
  • Birch Pollen Allergy - Therapeutics under Development by Companies
  • Birch Pollen Allergy - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Birch Pollen Allergy - Products under Development by Companies
  • Birch Pollen Allergy - Companies Involved in Therapeutics Development
    • ALK-Abello A/S
    • Allergopharma GmbH & Co. KG
    • Anergis SA
    • Biomay AG
    • Circassia Pharmaceuticals Plc
    • HAL Allergy BV
    • Stallergenes SAS
  • Birch Pollen Allergy - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Allergen for Birch Pollen Induced Allergic Rhinoconjunctivitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AllerT - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Birch Pollen Allergoid - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BM-31 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PL-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • STG-210 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Birch Pollen Allergy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Birch Pollen Allergy - Dormant Projects
  • Birch Pollen Allergy - Discontinued Products
  • Birch Pollen Allergy - Product Development Milestones
    • Featured News & Press Releases
      • Jun 07, 2016: Anergis to Present New Data on Lead Compound AllerT at the 35th European Academy of Allergy and Clinical Immunology Congress 2016
      • Apr 01, 2015: Anergis Announces Completion of Treatment in AllerT Phase II Dose-Ranging Trial
      • Mar 10, 2015: Positive Outcome of the PURETHAL Birch RUSH Study Results in an Approved, Accelerated up-dosing Regimen
      • Feb 23, 2015: Anergis Presents Sustained Efficacy Data from its AllerT Phase IIb Trial at the AAAAI Annual Meeting
      • Dec 11, 2014: Anergis Starts Phase II Dose Ranging Trial with Birch Pollen Allergy Vaccine AllerT
      • Sep 16, 2014: Anergis Reports Positive Long-Term Clinical Efficacy of Lead Compound AllerT
      • May 27, 2014: Anergis to Present New COP Allergy Vaccine Data at EAACI Conference 2014 in Copenhagen
      • Apr 23, 2014: Anergis Completes Enrolment in the Long-Term Efficacy Trial of Lead Compound AllerT
      • Feb 27, 2014: Phase IIb Results of Anergis´ Lead Compound AllerT to be Presented at 2014 AAAAI Annual Meeting in San Diego
      • Oct 21, 2013: Immunology Data Further Underline the Positive Outcome of a Phase IIb Trial of Anergis's Birch Pollen Allergy Vaccine AllerT
      • Sep 10, 2013: Anergis Reports Positive Phase IIb Data for Birch Pollen Allergy Vaccine AllerT
      • Jan 23, 2013: Anergis Obtains US Patent For Lead Product AllerT
      • Nov 08, 2012: Long-Term Immunomodulation Induced By Anergis's COP Allergy Vaccine AllerT Extends To Fourth Year After Treatment
      • Nov 06, 2012: Anergis Starts European Phase IIb Clinical Trial With AllerT In Patients With Allergy To Birch Pollen
      • Jan 24, 2011: Anergis Obtains Core Technology Patent Protection in the US
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Birch Pollen Allergy, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Birch Pollen Allergy - Pipeline by ALK-Abello A/S, H2 2016
  • Birch Pollen Allergy - Pipeline by Allergopharma GmbH & Co. KG, H2 2016
  • Birch Pollen Allergy - Pipeline by Anergis SA, H2 2016
  • Birch Pollen Allergy - Pipeline by Biomay AG, H2 2016
  • Birch Pollen Allergy - Pipeline by Circassia Pharmaceuticals Plc, H2 2016
  • Birch Pollen Allergy - Pipeline by HAL Allergy BV, H2 2016
  • Birch Pollen Allergy - Pipeline by Stallergenes SAS, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Birch Pollen Allergy - Dormant Projects, H2 2016
  • Birch Pollen Allergy - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Birch Pollen Allergy, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top